Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026338 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
A Phase 3 study of Pancreatic Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
- 20
- Study locations
NCT00026338 is a Phase 3 study of Pancreatic Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 569 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00026338, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG erlotinib hydrochloride
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- Sutter Health West Cancer Research Group - Greenbrae
- Loma Linda University Cancer Institute - Loma Linda
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Kenmar Research Institute - Los Angeles
- Century City Hospital - Los Angeles
- David Geffen School of Medicine - Los Angeles
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
Florida
- Florida Cancer Specialists - Fort Myers
- Oncology-Hematology Group of South Florida - Miami
- Ocala Oncology Center - Ocala
- Oncology & Hematology Associates of West Broward - Tamarac
- Moffitt Clinic at Tampa General Hospital - Tampa
Connecticut
- Davis, Posteraro, & Wasser, MDs, LLP - Manchester
- New Britain General Hospital - New Britain
- Eastern Connecticut Hematology and Oncology Associates - Norwich
- Hematology Oncology, P.C. - Stamford
Arizona
- Arizona Clinical Research Center - Tucson
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Central Georgia Hematology Oncology, P.C. - Macon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2001-10-29 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026338
The ClinicalTrials.gov registry entry for NCT00026338 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 569 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00026338 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00026338 about?
NCT00026338 is a clinical study titled "Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill ...
What is the current status of trial NCT00026338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2001-10-29. Estimated completion is 2009-02-10.
What conditions does trial NCT00026338 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00026338?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00026338?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026338 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.